0.6012
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
Moleculin Biotech Inc. Stock Analysis and ForecastExceptional risk-adjusted gains - PrintWeekIndia
What drives Moleculin Biotech Inc. stock priceUnprecedented market success - PrintWeekIndia
How high can Moleculin Biotech Inc. stock price go in 2025High-margin investment plays - jammulinksnews.com
Is Moleculin Biotech Inc. a good long term investmentConsistent triple-digit returns - jammulinksnews.com
What analysts say about Moleculin Biotech Inc. stockFree Risk Assessment Services - jammulinksnews.com
Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
Moleculin Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Exclusive: Moleculin CEO Shares Vision Behind Revolutionary Cancer Drug Pipeline in New Investor Presentation - Stock Titan
Moleculin Biotech Gains Approval for Phase 2B/3 AML Study - MSN
Moleculin Biotech Appoints Adriano Treve as Strategic Advisor - The Globe and Mail
MBRX Surges 29.65% on Strategic Hire and Phase 3 Momentum – Is This the Catalyst for a Biotech Breakout? - AInvest
Moleculin appoints former Roche executive as strategic advisor - Investing.com Australia
Moleculin appoints former Roche executive as strategic advisor By Investing.com - Investing.com Canada
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships - Santé log
Moleculin Biotech, Inc. Appoints Adriano Treve as Strategic Advisor to Enhance Partnerships and Advance Clinical Trials - Nasdaq
What makes Moleculin Biotech Inc. stock price move sharplySmart Trading With Safety Margin - Newser
Why Moleculin Biotech Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser
Moleculin Biotech Surges 19.5%—What's Fueling the Rally? - AInvest
Moleculin biotech highlights pivotal Phase 3 trials for Annamycin in AML with interim results expected in 2025 - MSN
Moleculin Biotech enters $6.5 million at-the-market equity offering agreement By Investing.com - Investing.com South Africa
Moleculin Biotech Enters New Stock Offering Agreement - TipRanks
Moleculin Biotech enters $6.5 million at-the-market equity offering agreement - Investing.com
Moleculin Acquires $2M Private Grant for Brain Tumor Trial at MD Anderson - BioTecNika
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans - GlobeNewswire
Moleculin receives Georgian approval for pivotal AML treatment trial By Investing.com - Investing.com India
Moleculin receives Georgian approval for pivotal AML treatment trial - Investing.com Australia
Moleculin Biotech Stock Soars 13.44% on Clinical Trial Expansion - AInvest
Moleculin Biotech, Inc. Secures RAMPA Approval for Phase 2B/3 MIRACLE Trial in Georgia, Expanding Clinical Recruitment Efforts - Nasdaq
MBRX gains RAMPA nod for pivotal Phase 2B/3 AnnAraC AML trial | THTX SEC FilingForm 6-K - Stock Titan
Moleculin's Phase 3 AML Treatment Trial Gains Momentum: 7 Patients Treated, 16 New Sites Coming - Stock Titan
Favourable Signals For Moleculin Biotech: Numerous Insiders Acquired Stock - simplywall.st
Moleculin Biotech (MBRX) Price Target Reduced to $13 by Roth Cap - GuruFocus
Moleculin Biotech Faces Nasdaq Delisting Warning - TipRanks
Healthcare Stocks to Watch: Catalyst Pharmaceuticals, AVITA Medical, and Moleculin Biotech. - AInvest
Moleculin Biotech Raises $5.9M in Public Offering - TipRanks
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):